

ALA-3000 Breaks Key Barriers in Ketamine Therapy for TRD

ALA-3000 is a subcutaneous, extended-release ketamine formulation designed for **once-weekly, biweekly, or monthly** dosing for treatment-resistant depression and fibromyalgia.

- Sustained-release profile for weeks without pronounced initial burst or dose dumping effect
- 25G Thin needle

- Clinically validated in a Phase I trial (NCT06965569) in US patients with TRD
- Favorable safety and tolerability profile
- No sedation, dissociation, psychosis-like effects, or commonly ketamine-reported AEs (e.g., blood pressure elevation, urinary toxicity)
- Durable antidepressant effects
- No reports of worsening suicidal ideation or suicidal behavior
- No abuse signals
- Potentially eliminates the mandatory ≥ 2 -hour post-dose on-site monitoring required with ketamine therapies.



First Monthly ketamine for treatment-resistant depression!

ALA-4000




- Weekly or biweekly apomorphine LAI for Parkinson's disease
- No specialized and complex devices, and zero home-management stress
- Solve the "OFF" period fluctuations
- Potentially lower risk of nausea and drug-induced dyskinesia

ALA-5000



- Monthly cariprazine LAI for Schizophrenia
- Pre-IND meeting completed
- IND-enabling studies are undertaken




Product	Indication	Duration	Preclin	Phase I	Phase II	Phase III
ALA-1000 (Buprenorphine)	Opioid use disorder	1-month ≥ 3 -month				
ALA-2000 (Naltrexone)	Alcohol/Opioid use disorder	1-month				
ALA-3000 (Ketamine)	Treatment-resistant depression	weekly, biweekly, 1-month				
ALA-4000 (Apomorphine)	Parkinson's disease	weekly, biweekly				
ALA-5000 (Third-generation antipsychotic)	Schizophrenia	1-month				




Long-acting injectables for CNS disorders

Pharmaceuticals Inc.



Light up Your Life!



Website



Alar Pharmaceuticals Inc.

+886-4-2463-7115

5F., No. 32, Keya Rd., Daya Dist., Taichung City 428015, Taiwan

✉ alar@alarpharm.com